Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01

K250073 · Tosoh Bioscience, Inc. · PDJ · Oct 3, 2025 · Clinical Chemistry

Device Facts

• Record ID: K250073
• Device Name: Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01
• Applicant: Tosoh Bioscience, Inc.
• Product Code: PDJ · Clinical Chemistry
• Decision Date: Oct 3, 2025
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.1373
• Device Class: Class 2

Indications for Use

The Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01 is intended for in vitro diagnostic use for the quantitative measurement of % hemoglobin A1c (HbA1c) (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in human venous whole blood and hemolysate specimens using ion-exchange high performance liquid chromatography (HPLC). This test is to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes, and for monitoring of long-term blood glucose control in individuals with diabetes mellitus.

Device Story

The Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01 is an automated clinical laboratory instrument for HbA1c quantification. It processes human venous whole blood or hemolysate samples via ion-exchange high-performance liquid chromatography (HPLC). The system hemolyzes and dilutes samples, injecting them onto a TSKgel GR01 HbA1c Column. Separation of hemoglobin fractions (A1a, A1b, HbF, LA1c+, SA1c, A0) occurs via step-gradient elution with three buffers of varying ionic strength. A flow cell monitors absorbance changes at 415nm (with 500nm background correction). The device identifies common hemoglobin variants (D, S, C, E) based on retention time windows. Output includes sample ID, date, percentage/retention time of fractions, SA1c percentage, and chromatograms. Results are stored in internal memory (up to 150,000 results) and exportable via USB. Healthcare providers use these results to diagnose diabetes and monitor long-term glycemic control, facilitating clinical management of diabetes mellitus.

Clinical Evidence

Bench testing only. Precision study (n=720) across three sites/analyzers showed total CVs 0.95-1.12% (NGSP) and 1.14-1.87% (IFCC). Linearity confirmed 3.9-16.9% HbA1c range (R²=1.000). Method comparison (n=135) against NGSP secondary reference laboratory showed high correlation (R=1.000) for both whole blood and hemolysate. Interference testing confirmed no significant bias from endogenous/exogenous substances or hemoglobin variants (HbS, HbC, HbD, HbE, HbA2, HbF).

Technological Characteristics

Ion-exchange HPLC; TSKgel GR01 cation exchange column; three-buffer step gradient elution; 415 nm absorbance detector. Automated dilution/hemolysis. Barcode reader for sample ID. Calibrated every 30 days or upon column change/QC failure. Standards: CLSI EP05-A3, EP06, EP07, EP09c-A3; IEC 60601-1-2.

Indications for Use

Indicated for use in clinical laboratories for quantitative measurement of HbA1c in human venous whole blood and hemolysate specimens to aid in the diagnosis of diabetes, identification of patients at risk for diabetes, and monitoring of long-term blood glucose control in individuals with diabetes mellitus.

Regulatory Classification

Identification

A hemoglobin A1c test system is a device used to measure the percentage concentration of hemoglobin A1c in blood. Measurement of hemoglobin A1c is used as an aid in the diagnosis of diabetes mellitus and as an aid in the identification of patients at risk for developing diabetes mellitus.

Special Controls

(b) Classification. Class II (special controls). Hemoglobin A1c test systems must comply with the following special controls: 1) The device must have initial and annual standardization verification by a certifying glycohemoglobin standardization organization deemed acceptable by FDA. 2) The premarket notification submission must include performance testing to evaluate precision, accuracy, linearity and interference, including the following: i) Performance testing of device precision must, at a minimum, use blood samples with concentrations near 5.0%, 6.5%, 8.0% and 12% hemoglobin A1c. This testing must evaluate precision over a minimum of 20 days using at least 3 lots of the device and 3 instruments, as applicable. ii) Performance testing of device accuracy must include a minimum of 120 blood samples that span the measuring interval of the new device and compare results of the new device to results of the standardized test method. Results must demonstrate little or no bias versus the standardized method. iii) Total error of the new device must be evaluated using single measurements by the new device compared to results of the standardized test method, and this evaluation must demonstrate a total error less than or equal to 6%. iv) Performance testing must demonstrate that there is little to no interference from common hemoglobin variants, including Hemoglobin C, Hemoglobin D, Hemoglobin E, Hemoglobin A2 and Hemoglobin S. 3) When assay interference from Hemoglobin F or interference with other hemoglobin variants with low frequency in the population is observed, a warning statement must be placed in a black box and must appear in all labeling material for these devices describing the interference and any affected populations.

*Classification.* Class II (special controls). The special controls for this device are:(1) The device must have initial and annual standardization verification by a certifying glycohemoglobin standardization organization deemed acceptable by FDA. (2) The premarket notification submission must include performance testing to evaluate precision, accuracy, linearity, and interference, including the following: (i) Performance testing of device precision must, at a minimum, use blood samples with concentrations near 5.0 percent, 6.5 percent, 8.0 percent, and 12 percent hemoglobin A1c. This testing must evaluate precision over a minimum of 20 days using at least three lots of the device and three instruments, as applicable. (ii) Performance testing of device accuracy must include a minimum of 120 blood samples that span the measuring interval of the device and compare results of the new device to results of a standardized test method. Results must demonstrate little or no bias versus the standardized method. (iii) Total error of the new device must be evaluated using single measurements by the new device compared to results of the standardized test method, and this evaluation must demonstrate a total error less than or equal to 6 percent. (iv) Performance testing must demonstrate that there is little to no interference from common hemoglobin variants, including Hemoglobin C, Hemoglobin D, Hemoglobin E, Hemoglobin A2, and Hemoglobin S. (3) When assay interference from Hemoglobin F or interference with other hemoglobin variants with low frequency in the population is observed, a warning statement must be placed in a black box and must appear in all labeling material for these devices describing the interference and any affected populations.

Predicate Devices

• Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 (K200904)

Submission Summary (Full Text)

{0}

FDA

U.S. FOOD & DRUG

ADMINISTRATION

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

ASSAY AND INSTRUMENT

## I Background Information:

A 510(k) Number

K250073

B Applicant

Tosoh Bioscience, Inc.

C Proprietary and Established Names

Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01

D Regulatory Information

| Product Code(s) | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| PDJ | Class II | 21 CFR 862.1373 - Hemoglobin A1c Test System | CH - Clinical Chemistry |
| LCP | Class II | 21 CFR 864.7470 - Glycosylated hemoglobin assay | HE - Hematology |

## II Submission/Device Overview:

A Purpose for Submission:

New Device.

B Measurand:

Glycosylated Hemoglobin (HbA1c)

C Type of Test:

Food and Drug Administration

10903 New Hampshire Avenue

Silver Spring, MD 20993-0002

www.fda.gov

{1}

Quantitative, Ion-exchange High Performance Liquid Chromatography (HPLC)

## III Intended Use/Indications for Use:

### A Intended Use(s):

See Indications for Use below

### B Indication(s) for Use:

The Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01 is intended for in vitro diagnostic use for the quantitative measurement of % hemoglobin A1c (HbA1c) (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in human venous whole blood and hemolysate specimens using ion-exchange high performance liquid chromatography (HPLC). This test is to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes, and for monitoring of long-term blood glucose control in individuals with diabetes mellitus.

### C Special Conditions for Use Statement(s):

- Rx - For Prescription Use Only
- This product is for IN VITRO DIAGNOSTIC use only
- For diagnosis purposes, results should be interpreted in conjunction with the patient's medical history and clinical findings.
- The HbA1c test is not suitable for use in:
- Analyzing samples collected from newborns.
- Diagnosing gestational diabetes.
- Diagnosing diabetes in patients with any condition where the lifespan of red blood cells is compromised, including recent significant or chronic blood loss, transfusions, significant iron deficiency, hemolytic diseases, hereditary spherocytosis, patients with hemoglobinopathies, with heterozygous sickle cell trait, or thalassemias.
- Diagnosing diabetes in patients with malignancies or severe chronic liver or kidney disease.
- In cases of rapidly evolving type 1 diabetes the increase of HbA1c values might be delayed compared to the acute increase in glucose concentrations. In these conditions diabetes mellitus must be diagnosed based on plasma glucose concentration and/or the typical clinical symptoms.
- Hemoglobin A1c testing should not replace glucose testing for type 1 diabetes, in pediatric patients and pregnant women.

### D Special Instrument Requirements:

The Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01

## IV Device/System Characteristics:

### A Device Description:

K250073 - Page 2 of 11

{2}

The Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01 (HLC-723GR01) is an automated high performance liquid chromatography (HPLC) that separates and reports stable hemoglobin A1c (HbA1c) in whole blood and hemolysate samples in both DCCT/NGSP % and IFCC mmol/mol units. The Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01 (or HLC-723GR01) analyzer is used with the GR01 cation exchange column (TSKgel GR01 HbA1c Column), GR01 HbA1c elution buffers (Buffer No. 1, 2 and 3) with varying salt concentrations, Hemolysis and Wash Solution, Hemoglobin A1c Calibrator Set and Hemoglobin A1c Control Set (levels 1 and 2).

## B Principle of Operation:

The HLC-723GR01 is based on the principle of ion exchange high-performance liquid chromatography (HPLC). The analyzer has two settings to allow HbA1c be measured using either venous whole blood samples in tubes (K2 EDTA or K3 EDTA) or using manually diluted venous whole blood samples (hemolysate) in a sample cup. The whole blood sample setting incorporates an automatic dilution that hemolyzes the sample. Separation of hemoglobin fractions is achieved by using differences in ionic interactions between the cation exchange group on the column resin surface and the hemoglobin components by a step gradient elution with three elution buffers of increasing ionic strengths. Inside the column, the net charges of the hemoglobin proteins interact with the negative charges on the surface of non-porous resin. The separated hemoglobin fractions pass through a detector that measures absorbance at 415 nm. The analyzer plots a chromatogram showing the changes in absorbance versus retention time, showing as a peak for each fraction on the resulting chromatogram. The % HbA1c is calculated and is displayed along with the chromatogram.

## C Instrument Description Information:

1. Instrument Name:

The Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01

2. Specimen Identification:

The built-in barcode reader reads the barcode label on the primary tube or vial adapter and the analyzer prints the barcode on the report in the ID field.

3. Specimen Sampling and Handling:

Venous whole blood samples collected in K2EDTA or K3EDTA can be stored at 25°C for 24 hours or at 4°C for 14 days. Samples frozen at -80°C are stable for 9 months.

4. Calibration:

The analyzer uses two levels of calibrators with different values of HbA1c (%). Calibration should be performed every 30 days, when a new column has been installed, when the analysis value of the QC control is out of the reference range, or the flow factor setting has been changed.

K250073 - Page 3 of 11

{3}

K250073 - Page 4 of 11

5. Quality Control:

It is recommended that at least two levels of controls be run on the GR01 analyzer at least once per day.

V Substantial Equivalence Information:

A Predicate Device Name(s):

Tosoh Automated Glycohemoglobin Analyzer HLC-723G8

B Predicate 510(k) Number(s):

K200904

C Comparison with Predicate(s):

| Device & Predicate Device(s): | K250073 | K200904 |
| --- | --- | --- |
| Device Trade Name | Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01 | Tosoh Automated Glycohemoglobin Analyzer HLC-723G8, v5.24F |
| General Device Characteristic Similarities | | |
| Intended Use/Indications For Use | Intended for in vitro diagnostic use for the measurement of % hemoglobin A1c (HbA1c) (DCCT/NGSP) and mol/mol hemoglobin A1c (IFCC) using ion-exchange high performance liquid chromatography (HPLC). This test is to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes, and for monitoring of long-term blood glucose control in individuals with diabetes mellitus. | Same |
| Test principle | Ion-exchange HPLC | Same |
| General Device Characteristic Differences | | |
| Sample Type | Human venous whole blood and hemolysate | Human venous whole blood |

{4}

VI Standards/Guidance Documents Referenced:

21 CFR 862.1373 – Special controls for Hemoglobin A1c test system

Clinical and Laboratory Standards Institute (CLSI) EP05 – A3: Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline – Third Edition

CLSI EP06: Evaluation of Linearity of Quantitative Measurement Procedures – Second Edition

CLSI EP07: Interference Testing in Clinical Chemistry; Approved Guideline – Third Edition

CLSI EP09c – A3: Measurement Procedure Comparison and Bias Estimation Using Patient Samples – Third Edition

IEC 60601-1-2 Edition 4.1 2020-09 CONSOLIDATED VERSION: Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests

VII Performance Characteristics (if/when applicable):

A Analytical Performance:

1. Precision/Reproducibility:

Precision studies were conducted using four K2EDTA venous whole blood samples containing HbA1c concentrations of approximately 5.0%, 6.5%, 8.0% and 12.0% from different donors and their corresponding hemolysates (manually diluted from the whole blood samples). Samples were tested at three sites on three analyzers (HLC-723GR01) with three lots of reagents, each sample was analyzed in duplicate per run, two runs per day, for 20 days. The results are shown below.

All analyzers combined (n=720) with NGSP (%) unit.

| Whole Blood | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean % HbA1c | Repeatability | | Between-Run | | Between-Day | | Between-Lot | | Between Instruments | | Total | |
| | SD | CV(%) | SD | CV(%) | SD | CV(%) | SD | CV(%) | SD | CV(%) | SD | CV(%) |
| 4.91% | 0.024 | 0.48 | 0.000 | 0.00 | 0.024 | 0.48 | 0.028 | 0.57 | 0.025 | 0.52 | 0.051 | 1.03 |
| 6.88% | 0.026 | 0.38 | 0.015 | 0.22 | 0.043 | 0.62 | 0.050 | 0.73 | 0.011 | 0.17 | 0.074 | 1.07 |
| 8.24% | 0.025 | 0.31 | 0.016 | 0.20 | 0.049 | 0.59 | 0.058 | 0.71 | 0.017 | 0.21 | 0.084 | 1.01 |
| 11.79% | 0.031 | 0.26 | 0.023 | 0.19 | 0.063 | 0.53 | 0.078 | 0.66 | 0.032 | 0.27 | 0.112 | 0.95 |
| Hemolysate | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean % HbA1c | Repeatability | | Between-Run | | Between-Day | | Between-Lot | | Between Instruments | | Total | |
| | SD | CV(%) | SD | CV(%) | SD | CV(%) | SD | CV(%) | SD | CV(%) | SD | CV(%) |
| 4.90% | 0.017 | 0.35 | 0.012 | 0.25 | 0.024 | 0.50 | 0.029 | 0.60 | 0.027 | 0.56 | 0.052 | 1.05 |

K250073 - Page 5 of 11

{5}

| 6.87% | 0.028 | 0.40 | 0.011 | 0.15 | 0.042 | 0.61 | 0.057 | 0.83 | 0.005 | 0.07 | 0.077 | 1.12 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 8.25% | 0.025 | 0.30 | 0.012 | 0.14 | 0.050 | 0.61 | 0.057 | 0.69 | 0.016 | 0.20 | 0.082 | 1.00 |
| 11.82% | 0.032 | 0.27 | 0.021 | 0.18 | 0.065 | 0.55 | 0.073 | 0.62 | 0.043 | 0.37 | 0.114 | 0.96 |

All analyzers combined (n=720) with IFCC (mmol/mol) unit.

| Whole Blood | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean HbA1c (mmol/mol) | Repeatability | | Between-Run | | Between-Day | | Between-Lot | | Between Instruments | | Total | |
| | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) |
| 30 | 0.188 | 0.62% | 0.000 | 0.00% | 0.280 | 0.93% | 0.365 | 1.21% | 0.252 | 0.84% | 0.557 | 1.85% |
| 52 | 0.155 | 0.30% | 0.070 | 0.14% | 0.402 | 0.78% | 0.551 | 1.07% | 0.169 | 0.33% | 0.723 | 1.40% |
| 67 | 0.153 | 0.23% | 0.127 | 0.19% | 0.514 | 0.77% | 0.542 | 0.81% | 0.138 | 0.21% | 0.785 | 1.18% |
| 105 | 0.166 | 0.16% | 0.186 | 0.18% | 0.696 | 0.66% | 0.862 | 0.82% | 0.387 | 0.37% | 1.200 | 1.14% |
| Hemolysate | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean HbA1c (mmol/mol) | Repeatability | | Between-Run | | Between-Day | | Between-Lot | | Between Instruments | | Total | |
| | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) | SD | CV (%) |
| 30 | 0.125 | 0.42% | 0.140 | 0.47% | 0.279 | 0.93% | 0.378 | 1.26% | 0.246 | 0.82% | 0.562 | 1.87% |
| 52 | 0.141 | 0.27% | 0.076 | 0.15% | 0.401 | 0.78% | 0.598 | 1.16% | 0.145 | 0.28% | 0.752 | 1.46% |
| 67 | 0.137 | 0.20% | 0.131 | 0.20% | 0.520 | 0.78% | 0.559 | 0.84% | 0.154 | 0.23% | 0.801 | 1.20% |
| 106 | 0.191 | 0.18% | 0.194 | 0.18% | 0.693 | 0.66% | 0.860 | 0.81% | 0.504 | 0.48% | 1.244 | 1.18% |

2. Linearity:

A linearity study was conducted using Tosoh Automated Analyzer HLC 723GR01 according to the CLSI guideline EP06. A total of eleven 11 venous whole blood specimens collected in K2EDTA anticoagulant tubes were prepared by mixing samples containing low (3.92%) and high (20.41%) levels of HbA1c. Each sample was tested in replicates of four. The mean measured HbA1c values were compared to the expected values. The results of regression analysis:

NGSP: $y = 1.001x + 0.06199$ , $R^2 = 1.000$

IFCC: $y = 1.001x + 0.7028$ , $R^2 = 1.000$

The linearity study supports the claimed measuring range of $3.9\%$ to $16.9\%$ HbA1c (NGSP), corresponding to a measuring range of 19 - 161 mmol/mol HbA1c (IFCC).

3. Analytical Specificity/Interference:

Endogenous and Exogenous Substances:

Interference Studies were performed to assess the impact of endogenous and exogenous substances on the performance of the Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01. Three K2EDTA venous whole blood samples containing approximately $5\%$ , $6.5\%$ and $10\%$ HbA1c were separated into a control sample with no potential interferent added and a test sample containing the potentially interfering substances. Significant interference was

K250073 - Page 6 of 11

{6}

defined by the sponsor as a % difference greater than ± 5% between the mean of the test sample replicates and control sample replicates. The following substances demonstrated no significant interference at the concentrations described below:

| Endogenous Substance | Highest concentration tested with no significant interference |
| --- | --- |
| Albumin | 20 g/dL |
| Ascorbic Acid | 300 mg/dL |
| Bilirubin - Conjugated | 100 mg/dL |
| Bilirubin - Unconjugated | 100 mg/dL |
| Rheumatoid Factor | 750 IU/mL |
| Triglycerides | 6,000 mg/dL |
| Exogenous Substance | Highest concentration tested with no significant interference |
| --- | --- |
| Acetaminophen | 20 mg/dL |
| Acetylsalicylic acid | 330 mg/dL |
| Ampicillin | 1000 mg/dL |
| Cefoxitin | 2500 mg/dL |
| Cyclosporin | 0.7 mg/dL |
| Doxycycline | 50 mg/dL |
| Heparin | 5000 U/L |
| Ibuprofen | 50 mg/dL |
| Levodopa | 20 mg/dL |
| Metformin | 5 mg/dL |
| Methyldopa | 30 mg/dL |
| Metronidazole | 200 mg/dL |
| Phenylbutazone | 400 mg/dL |
| Rifampicin | 6.4 mg/dL |
| Salicylic Acid | 60 mg/dL |
| Theophylline | 10 mg/dL |

## Cross reactivity:

Three venous whole blood samples collected in K2EDTA anticoagulant tubes, with HbA1c levels at approximately 5%, 6.5% and 10% HbA1c were used to assess potential cross-reacting substances that could interfere with the Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01 performance. Samples were separated into a control sample with no treatment and a test sample containing the potentially interfering cross reactant. No significant interference was defined by the sponsor as within ± 5% change between the mean of the test sample replicates and the mean of the control sample replicates. Results are shown below:

K250073 - Page 7 of 11

{7}

| Hemoglobin Derivatives | Highest Concentration Level Tested with No Interference |
| --- | --- |
| Labile Hb (glucose) | 2000 mg/dL |
| Carbamylated Hb (Sodium Cyanate) | 25 mg/dL |
| Aldehyde Hb (Acetaldehyde) | 25 mg/dL |
| Acetylated Hb (Acetylsalicylic Acid) | 50 mg/dL |

## Hemoglobin Variant Interference:

Hemoglobin variant studies were conducted using K2EDTA venous whole blood samples containing hemoglobin variants HbS, HbC, HbD, HbE, HbA2, and HbF. Results obtained using the Tosoh Automated Analyzer HLC-723GR01 were compared to results obtained using a valid comparator method. No significant interference was defined by the sponsor as a relative bias of ≤ ± 7% at around medical decision level of 6.5% and 8.0% HbA1c (≤ ± 6% for HbF), when compared to the comparator method.

| Variant | n | HbA1c Range | Variant Range | Relative % Bias (Range of %Bias) Relative to the Comparator | |
| --- | --- | --- | --- | --- | --- |
| | | | | ~6.5 % HbA1c | ~8.0 % HbA1c |
| HbC | 25 | 4.6% to 14.3% | 30.3% to 38.8% | 2.79 (0.74 to 4.65) | 1.80 (-0.61 to 3.85) |
| HbD | 22 | 5.7% to 10.9% | 24.3% to 42.7% | 0.50 (-3.08 to 5.26) | -1.16 (-4.71 to 1.27) |
| HbE | 34 | 5.0% to 12.8% | 19.5% to 31.4% | 1.54 (-3.57 to 4.92) | 2.08 (0.00 to 7.19) |
| HbS | 29 | 4.7% to 14.4% | 26.6% to 42.7% | 2.49 (1.57 to 3.91) | 2.71 (1.99 to 4.43) |
| HbA2 | 33 | 4.7% to 14.3% | 3.5% to 6.7% | 2.51 (0.77 to 4.65) | 1.26 (-0.61 to 2.99) |
| HbF | 33 | 5.5% to 11.7% | 3.8% to 32.2% | -1.2 (-3.0 to 1.5) | -2.6 (-4.2 to 0.8) |

## 4. Assay Reportable Range:

The reportable range for this device is 3.9% to 16.9% HbA1c.

## 5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

The assigned HbA1c values of the Tosoh Automated Analyzer HLC-723GR01 are certified with the National Glycohemoglobin Standardization Program (NGSP). See NGSP website for current certification at http://www.ngsp.org. The final reportable result is traceable to both the International Federation of Clinical Chemistry (IFCC) and the Diabetes Control and Complications Trial (DCCT). The International Federation of Clinical Chemistry (IFCC) units of mmol/mol are calculated using the Master Equation NGSP (%) = 0.09148 x IFCC (mmol/mol) + 2.152. HbA1c results are provided to the customers using two different units: NGSP equivalent units (%) and IFCC equivalent units (mmol/mol).

K250073 - Page 8 of 11

{8}

6. Detection Limit:

Not applicable.

7. Assay Cut-Off:

Not applicable.

8. Accuracy (Instrument):

See method comparison study below.

9. Carry-Over:

A carryover study was conducted and found to be acceptable.

## B Comparison Studies:

1. Method Comparison with Predicate Device:

A method comparison study was performed using 135 venous K2 EDTA samples and the respective manual hemolysates. obtained on the candidate device HLC-723GR01 were compared to results obtained on the comparator method at a NGSP secondary reference laboratory. The HbA1c concentrations of the whole blood samples ranged from 4.3% to 16.5% and the corresponding hemolysate samples ranged from 4.2% to 16.6%, according to the comparator. Each sample was tested in singlicate on one of the three investigational analyzers across three different sites and in triplicate on the comparator method. Passing-Bablok Regression analyses were performed for the candidate device versus the comparator method.

The distribution of samples used in the study is summarized below:

| %HbA1c | # whole blood samples tested (% of total) | # hemolysate tested (% of total) |
| --- | --- | --- |
| ≤5% | 5 (3.7%) | 5 (3.7%) |
| >5.0 – 6.0% | 16 (11.9%) | 15 (11.1%) |
| >6.0 – 6.5% | 31 (23%) | 32(23.7%) |
| >6.5 – 7.0% | 31 (23%) | 32 (23.7%) |
| >7.0 – 8.0% | 21 (15.6%) | 20 (14.8%) |
| >8.0 – 9.0% | 9 (6.7%) | 10 (7.4%) |
| >9.0% | 22 (16.3%) | 21 (15.6%) |
| Total | 135 | 135 |

Summary of Passing-Bablok regression results in NSGP units are as follows:

| Sample type (n=135) | Slope | Slope 95% CI | Intercept | Intercept 95% CI | R |
| --- | --- | --- | --- | --- | --- |
| Whole Blood | 1.0045 | 1.000 to 1.0135 | -0.0222 | -0.0743 to 0.000 | 1.000 |
| Hemolysate | 1.0125 | 1.0039 to 1.0189 | -0.0788 | -0.1226 to -0.0241 | 1.000 |

K250073 - Page 9 of 11

{9}

Total Error:

The bias estimates determined from the method comparison study results using Passing-Bablok regression and the precision determined in the precision study were used to determine the total error (TE) of the device at each of the HbA1c levels was calculated as follows:

$$
\% \mathrm{TE} = \left|\% \mathrm{Bias}\right| + (1.96 \times \% \mathrm{CV}) \times (1 + \% \mathrm{Bias} / 100)
$$

| | %HbA1c | %Bias | %CV | %TE |
| --- | --- | --- | --- | --- |
| Whole Blood | 5.0% | 0.006 | 1.03 | 2.02 |
| | 6.5% | 0.108 | 1.07 | 2.21 |
| | 8.0% | 0.172 | 1.01 | 2.16 |
| | 12.0% | 0.265 | 0.95 | 2.13 |
| Hemolysate | 5.0% | 0.326 | 1.05 | 2.38 |
| | 6.5% | 0.038 | 1.12 | 2.23 |
| | 8.0% | 0.265 | 1.00 | 2.23 |
| | 12.0% | 0.593 | 0.96 | 2.49 |

2. Matrix Comparison:

A matrix Comparison study was conducted using a total of 51 paired venous K2EDTA and K3EDTA venous whole blood samples spanning the HbA1c measuring range and the results support the use of the HbA1c assay with sample collected in K2EDTA and K3EDTA.

| Method of Analysis | n | Slope | Intercept | r |
| --- | --- | --- | --- | --- |
| Ordinary Deming | 51 | 0.9957 | 0.0211 | 1.000 |
| Passing-Bablok | 51 | 1.0000 | 0.0000 | 1.000 |

C Clinical Studies:

1. Clinical Sensitivity:

Not applicable.

2. Clinical Specificity:

Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):

Not applicable.

D Clinical Cut-Off:

Not applicable.

E Expected Values/Reference Range:

Reference Ranges (non-diabetic): HbA1c 4.0-6.0 % (mean 5.0 %, SD 0.5 %).

K250073 - Page 10 of 11

{10}

| | In NGSP units | In IFCC units | Comment |
| --- | --- | --- | --- |
| HbA1c | ≥ 6.5 % | ≥ 48 mmol/mol | Cutoff point to diagnose diabetes |
| HbA1c | 5.7 - 6.4% | 39 – 47 mmol/mol | Increased risk for diabetes (prediabetes) |

Reference:
American Diabetes Association. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021; 44 (Suppl. 1), S15-33.

F Other Supportive Instrument Performance Characteristics Data:
Additional studies were conducted to support the STAT function of the analyzer and the automatic dilution feature of the analyzer.

VIII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.

IX Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

K250073 - Page 11 of 11